Dr. Alexander Fleming is Founder and Executive Chairman of Kinexum and President and Co-Founder of Kitalys Institute. Dr. Fleming received his M.D. and internal medicine training from Emory, and did fellowships in endocrinology at Vanderbilt and in metabolism at the National Institutes of Health, where he was a senior fellow.
At the US Food and Drug Administration from 1986–98, Dr. Fleming was responsible for therapies related to nutrition; disorders of growth, development, and reproduction; diabetes and its complications; and other metabolic and endocrine diseases. He led reviews of landmark approvals including metformin and the first statin, insulin analog, PPAR-agonist, and growth hormone for non-GH deficiency indications. He helped shape FDA policies and practices related to therapeutic review and regulatory communication. He was a major contributor to FDA’s Good Review Practice (GRP) initiative and led the committee responsible for education and training at FDA’s Center for Drug Evaluation and Research (CDER). He conceived of and directed the first FDA pilot project to utilize the internet for regulatory communication.
Numerous international institutions have sought his regulatory and technical expertise, including the World Health Organization, where he was stationed by FDA during 1991–92. Dr. Fleming was a member of the expert working groups on Good Clinical Practices and General Considerations for Clinical Trials of the International Conference on Harmonization (ICH) and participated on other ICH committees including the Common Technical Document working group.
Dr. Fleming has authored many scientific articles, books, and book chapters. He has been a member of many corporate and advisory boards to academic and commercial institutions and professional societies. He serves on the joint technology working groups of the European Association for the Study of Diabetes and American Diabetes Association.
Dr. Fleming coined the term “metabesity,” which refers to the constellation of cancer, heart and neurologic diseases, diabetes, and the aging process itself, all which share targetable root causes. He co-founded the Targeting Metabesity Conference, since renamed the Targeting Healthy Longevity Conference (THL), in 2017. Since the inaugural meeting in London, over 200 THL sessions have been produced to date. In 2020, Dr. Fleming started the not-for-profit Kitalys Institute to produce THL and other meetings and support initiatives involving FDA and the US Congress.